Follicle stimulating hormone glyco-optimised - Glycotope

Drug Profile

Follicle stimulating hormone glyco-optimised - Glycotope

Alternative Names: Follicle stimulating hormone - Glycotope; FSH-GEX; Glyco-optimized follicle-stimulating hormone - Glycotope; GT-GP-2.4 GEX

Latest Information Update: 13 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glycotope
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Female infertility

Most Recent Events

  • 13 Jul 2016 Phase-III clinical trials in Female infertility (SC) before July 2016
  • 04 Sep 2015 Clinical development of follicle stimulating hormone glyco-optimized is ongoing
  • 26 Mar 2014 Glycotope completes a phase II trial in Female infertility in Germany (EudraCT 2012-003006-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top